Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine H Smith

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
The Journal of Investigative Dermatology|October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
Clinical and Experimental Dermatology|May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohortOras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 2, 2025
Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta-analysisDavid Gleeson, Mark Corbett, Shern P Choy, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The British Journal of Dermatology|November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control studyKayleigh J Mason, Oras A Alabas, Nick Dand, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
The Journal of Investigative Dermatology|March 27, 2021
Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy ShowcaseZenas Z N Yiu, Jonathan N W N Barker, Michael R Barnes, et al.
Dermatology and Therapy|October 31, 2025
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised EvidenceHeber Rew Bright Bright, Duc Binh Phan, Amna Zahid, et al.
The British Journal of Dermatology|February 17, 2024
Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods studyDavid Gleeson, Maneeha Naveed, Lucy Moorhead, et al.
JAMA Dermatology|December 6, 2023
Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisAli Al-Janabi, Oras A Alabas, Zenas Z N Yiu, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
The Journal of Investigative Dermatology|October 30, 2017
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Ireny Y K Iskandar, Richard B Warren, Mark Lunt, et al.
Clinical and Experimental Dermatology|May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohortOras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 2, 2025
Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta-analysisDavid Gleeson, Mark Corbett, Shern P Choy, et al.
Nature Communications|January 30, 2024
Single-cell analysis of psoriasis resolution demonstrates an inflammatory fibroblast state targeted by IL-23 blockadeLuc Francis, Daniel McCluskey, Clarisse Ganier, et al.
The British Journal of Dermatology|November 12, 2023
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case-control studyKayleigh J Mason, Oras A Alabas, Nick Dand, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
The Journal of Investigative Dermatology|March 27, 2021
Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy ShowcaseZenas Z N Yiu, Jonathan N W N Barker, Michael R Barnes, et al.
Dermatology and Therapy|October 31, 2025
Serious Infection Risk with Systemic Treatments for Psoriasis: A Systematic Review and Network Meta-analysis Combining Randomised and Non-randomised EvidenceHeber Rew Bright Bright, Duc Binh Phan, Amna Zahid, et al.
The British Journal of Dermatology|February 17, 2024
Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods studyDavid Gleeson, Maneeha Naveed, Lucy Moorhead, et al.
JAMA Dermatology|December 6, 2023
Risk of Paradoxical Eczema in Patients Receiving Biologics for PsoriasisAli Al-Janabi, Oras A Alabas, Zenas Z N Yiu, et al.
Pageof 17